Targeting Signaling Pathways in Solid Tumors Part A

1st Edition, Volume 385 - April 23, 2024
Imprint: Academic Press
Editors: Sumit Mukherjee, Kaushiki Chatterjee
Language: English
Hardback ISBN:
9 7 8 - 0 - 4 4 3 - 2 3 5 4 6 - 7
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 2 3 5 4 7 - 4

Targeting Signaling Pathways in Solid Tumors, Part A, Volume 385 in the International Review of Cell and Molecular Biology series, highlights new advances in the field, with t… Read more

Purchase options

BLOOM INTO SPRING SAVINGS

Save up to 25% on books and eBooks!

Shop now

Institutional subscription on ScienceDirect

Request a sales quote

Targeting Signaling Pathways in Solid Tumors, Part A, Volume 385 in the International Review of Cell and Molecular Biology series, highlights new advances in the field, with this new volume presenting interesting chapters on topics such as Drugging the Undruggable: Advances in Targeting KRAS Signaling in Solid Tumors, Emerging Trends in Gastrointestinal Cancers: Targeting Developmental Pathways in their Carcinogenesis and Tumor Progression, Importance of targeting various cell signaling pathways in solid cancers, Targeting signaling pathways in cancer stem cells: a potential approach for developing novel anticancer therapeutics, Factors affecting heterogeneity in breast cancer microenvironment: A narrative review, and much more.

Additional sections cover Exploring TLR Signaling Pathways as Promising Targets in Cervical Cancer: The Road Less Travelled

Cover image
Title page
Table of Contents
Series Page
Copyright
Contributors
Chapter One: Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors
Abstract
1 Introduction and significance of KRAS proteins
2 Overview of KRAS regulation and signaling
3 KRAS mutations in solid tumors
4 Mechanisms of KRAS signaling pathway activation in solid tumors
5 Biochemical heterogeneity of KRAS mutations: diverse paths to oncogenicity
6 KRAS mutations: immunosuppressive tumor microenvironment & tumor immune escape
7 KRAS-driven mice models: milestones in cancer modeling
8 Therapeutic targets in KRAS signaling pathways
9 Adaptation and acquired resistance to treatment
10 Concluding remarks and future perspectives
References
Chapter Two: Emerging trends in gastrointestinal cancers: Targeting developmental pathways in carcinogenesis and tumor progression
Abstract
Abbreviations
1 Introduction
2 Current therapeutic modalities of gastro-intestinal cancers
3 Role of developmental pathways in carcinogenesis of gastro-intestinal cancers
4 Colon cancer
5 Hepatocellular cancer
6 Colorectal cancer, it’s signaling and developmental pathway
7 Gallbladder cancer, it’s signaling and developmental pathway
8 Conclusion
Acknowledgment
References
Chapter Three: Importance of targeting various cell signaling pathways in solid cancers
Abstract
1 Introduction
2 Major Pathways involved in solid tumor
3 Hedgehog signaling
4 PI3K/AKT pathway
5 WNT/β-catenin signaling
6 NOTCH signaling
7 Hippo signaling
8 p53 signaling
9 Immune-checkpoint modulators
10 PD-1/PD-L1 pathway
11 CTLA-4 pathway
12 Heat shock proteins and immune response pathways
13 Endocrine therapy in cancer
14 Conclusion
References
Chapter Four: Targeting signaling pathways in cancer stem cells: A potential approach for developing novel anti-cancer therapeutics
Abstract
1 Introduction
2 Cancer stem cells
3 CSCs characteristics
4 Surface markers of CSCs
5 Signaling pathways involved in CSCs growth and proliferation
6 Targeting signaling pathways in CSCs
7 Crosstalk between signaling cascades in CSCs
8 Molecular players cross-talking between Wnt, Notch, and HH pathways
9 Plausible therapeutics targeting crosstalk molecules in signaling pathways
10 Conclusion
References
Chapter Five: Factors affecting heterogeneity in breast cancer microenvironment: A narrative mini review
Abstract
1 Introduction
2 Exploring the factors that impact the tumor heterogeneity
3 Impact of immune heterogeneity on cancer therapy response
4 Conclusions and future perspectives
Acknowledgments
References
Chapter Six: Exploring TLR signaling pathways as promising targets in cervical cancer: The road less traveled
Abstract
1 Cervical cancer and TLR
2 TLR signaling pathway
3 Mechanisms of TLR signaling pathway activation in cervical cancer
4 Therapeutic targets in TLR signaling pathways
5 Present status of TLR-based cancer ligands
6 Clinical trials of TLR pathway inhibitors in cervical cancer
7 Challenges and limitations of TLR pathway inhibitors in cervical cancer
8 Ongoing research and future directions
9 Conclusions
References

Sumit Mukherjee

I am a dynamic scientist with broad knowledge and research experience in cancer biology and cancer immunology. I am a highly skilled researcher with exceptional leadership and team-building capabilities. I have 10+ years of cancer research experience in academia as PhD student and Postdoctoral researcher. I have a track record of presenting and publishing scientific data in a timely and organized fashion as attested by my publication record of 12 published research articles with 6 as first-author. I am also a subject matter expert in preclinical cancer immunology as evidenced by my authored review articles with being co-corresponding author for one such review article. I have frequently peer-reviewed multiple articles for publication as peer-reviewer and guest editor. My Postdoctoral work focused on a novel immunosuppressive/protumor cancer cell expressing enzyme ART1’s discovery and further developing it as a therapeutic target in lung cancers and melanoma tumors utilizing murine in vivo models and patient samples. My doctoral research specialized in natural product-mediated (like curcumin) therapeutic intervention of cancers by modulating cancer cell signaling and cancer micro-environment immune system. My doctoral research also involved studying the mechanistic underpinning of cancer cell signaling & tumor microenvironment immunology for therapeutic targeting of brain tumors and cervical cancer models.

Affiliations and expertise

Cardiothoracic and Vascular Surgery,Albert Einstein College of Medicine Bronx

Kaushiki Chatterjee

As a skilled scientist with expertise in cancer biology, stem cell biology, and epigenetics, I am deeply passionate about advancing scientific knowledge. In my current postdoctoral role, I investigate the role of disease-relevant histone modifiers in shaping the epigenetic landscape of stem cells. My active involvement in multiple projects demonstrates my commitment to collaboration and leveraging collective knowledge to achieve impactful results. I have a track record of mentoring students and actively encouraging diversity in STEM, especially among women pursuing research careers. In my doctoral research, I contributed to understanding the anti-tumor potential of plant polyphenols in cervical cancer. I have published several research and review articles in cancer biology and stem cell epigenetics Through my multifaceted contributions over the course of over 10 years, I aim to inspire the next generation of scientists while leaving a lasting impact on scientific endeavors. Edit

Affiliations and expertise

Medicine Weill Cornell Medicine, New York

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health